A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results

7207 Background: The role of campthotecins in small cell lung cancer (SCLC) is emerging, and 5-day regimens with topetecan alone or with cisplatin have been shown to be active and tolerable. In order to provide a more feasible regimen for patients with extensive disease we developed a three-day regimen of topetecan and cisplatin. Preliminary data has previously been presented and we now present the final, updated results with a median follow-up time of 18 months. This investigators initiated study was supported by a grant from GlaxoSmithKline. Methods: This phase II study was planned to include 43 patients with histologically confirmed SCLC, extensive stage of disease, age 18–75 and WHO performance status 0–2. Patients received topetecan 2.0 mg/m2 on day 1–3 and cisplatin 50 mg/m2 on day 3, repeated every 3 weeks, for a maximum of 6 cycles. Patients with progressive disease (PD) or no-change (NC) after 3 cycles go off-study. Results: From May 2001 to September 2003, a total of 43 patients were included. A...